Across the recent three months, 9 analysts have shared their insights on Hims & Hers Health HIMS, expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 0 | 6 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 3 | 0 | 0 |
Analysts have recently evaluated Hims & Hers Health and provided 12-month price targets. The average target is $19.67, accompanied by a high estimate of $26.00 and a low estimate of $13.00. This upward trend is apparent, with the current average reflecting a 20.23% increase from the previous average price target of $16.36.
Analyzing Analyst Ratings: A Detailed Breakdown
A comprehensive examination of how financial experts perceive Hims & Hers Health is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $18.00 | $16.00 |
| Glen Santangelo | Jefferies | Raises | Hold | $23.00 | $14.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $26.00 | $22.00 |
| Michael Cherny | B of A Securities | Raises | Buy | $22.00 | $17.25 |
| Maria Ripps | Canaccord Genuity | Raises | Buy | $24.00 | $20.00 |
| Daniel Grosslight | Citigroup | Raises | Neutral | $20.00 | $16.00 |
| George Hill | Deutsche Bank | Raises | Hold | $16.00 | $14.00 |
| Korinne Wolfmeyer | Piper Sandler | Raises | Neutral | $13.00 | $11.00 |
| Glen Santangelo | Jefferies | Lowers | Hold | $15.00 | $17.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Hims & Hers Health. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Hims & Hers Health compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Hims & Hers Health's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Hims & Hers Health's market standing. Stay informed and make well-considered decisions with our Ratings Table.
Stay up to date on Hims & Hers Health analyst ratings.
Discovering Hims & Hers Health: A Closer Look
Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, primary care, and more.
Understanding the Numbers: Hims & Hers Health's Finances
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Hims & Hers Health's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 45.81%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Hims & Hers Health's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 4.0%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Hims & Hers Health's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 3.23%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Hims & Hers Health's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.5% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Hims & Hers Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.03.
What Are Analyst Ratings?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
